ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 53 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $240 | -42.6% | 321,360 | -25.4% | 0.00% | -100.0% |
Q2 2023 | $418 | +5.6% | 430,555 | -4.9% | 0.00% | 0.0% |
Q1 2023 | $396 | -21.9% | 452,860 | -14.9% | 0.00% | 0.0% |
Q4 2022 | $507 | -99.9% | 532,260 | -27.1% | 0.00% | 0.0% |
Q3 2022 | $804,000 | -26.4% | 730,598 | -19.1% | 0.00% | 0.0% |
Q2 2022 | $1,093,000 | +40.3% | 903,100 | +149.3% | 0.00% | 0.0% |
Q1 2022 | $779,000 | +20.4% | 362,314 | +564.8% | 0.00% | 0.0% |
Q4 2021 | $647,000 | -21.6% | 54,500 | +2.4% | 0.00% | 0.0% |
Q3 2021 | $825,000 | – | 53,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |